Citadel Advisors
BTAI icon

Citadel Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Citadel Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+149,220
New +$175K ﹤0.01% 11950
2025
Q3 		– Sell
-11,378
Closed -$20.6K – 12820
2025
Q2 		$20.6K Buy
+11,378
New +$18.8K ﹤0.01% 12097
2024
Q2 		– Sell
-2,540
Closed -$85K – 14303
2024
Q1 		$115K Buy
2,540
+2,207
+663% +$105K ﹤0.01% 11167
2023
Q4 		$15.7K Sell
333
-561
-63% -$31.2K ﹤0.01% 12821
2023
Q3 		$36.2K Sell
894
-14
-2% -$1.42K ﹤0.01% 12123
2023
Q2 		$96.8K Sell
908
-4,369
-83% -$1.45M ﹤0.01% 10994
2023
Q1 		$1.58M Buy
5,277
+2,364
+81% +$1.01M ﹤0.01% 5821
2022
Q4 		$1M Sell
2,913
-655
-18% -$158K ﹤0.01% 6815
2022
Q3 		$675K Buy
3,568
+821
+30% +$191K ﹤0.01% 7814
2022
Q2 		$581K Sell
2,747
-235
-8% -$49.4K ﹤0.01% 8302
2022
Q1 		$997K Sell
2,982
-7
-0.2% -$2.03K ﹤0.01% 7697
2021
Q4 		$972K Buy
2,989
+920
+44% +$395K ﹤0.01% 8038
2021
Q3 		$1M Sell
2,069
-2,910
-58% -$1.28M ﹤0.01% 8138
2021
Q2 		$2.31M Buy
4,979
+555
+13% +$303K ﹤0.01% 6227
2021
Q1 		$3.06M Sell
4,424
-46,466
-91% -$37.4M ﹤0.01% 5397
2020
Q4 		$37.6M Buy
50,890
+4,039
+9% +$3.15M 0.01% 1196
2020
Q3 		$32.5M Buy
46,851
+27,228
+139% +$20.4M 0.01% 1159
2020
Q2 		$16.6M Buy
+19,623
New +$12.8M 0.01% 1673

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's BTAI Position: Q2 2026 in Review

Citadel Advisors opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 149,220 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #11950 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BTAI as recently as Q2 2025.

Citadel Advisors first reported a position in BTAI in Q2 2020 and has held it in 18 quarters since. The position peaked at $37.6M in Q4 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Citadel Advisors held 149,220 shares of BioXcel Therapeutics worth $210K as of Q2 2026.
  • BioXcel Therapeutics was a new Citadel Advisors position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11950 holding.
  • Citadel Advisors first reported a position in BioXcel Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • Citadel Advisors's BioXcel Therapeutics position peaked at $37.6M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.